Regeneron is a scientist’s drug company. Founded by a pair of them in 1988, they run the biotech in a way that employees say sets it apart from big pharma. “The focus is not on the bottom line but on the patient,” says one. Of particular pride: Regeneron’s commitment to R&D and its “endless [drug] pipeline.” Read Great Place to Work review here.
Looking for leads, investment insights, or competitive intelligence?
News about Regeneron Pharmaceuticals
Amgen says Repatha sold $271 million in the first half of 2018, despite earlier predictions of multi-billion-dollar sales.
Scientists are ready to move an experimental treatment into phase 1 trials.
“We should only be working on two things, health and the freaking environment.”
But Dupixent's high cost could be a problem.